After Decades of Fighting Pancreatic Cancer, Here’s Why I’m More Optimistic Than Ever

Liz Jaffee

My journey to fighting pancreatic cancer from the front lines began long before I became an oncologist. It began with the death of my uncle.

In 1986, my uncle died of pancreatic cancer at the age of 51. I was an intern at the time. He was diagnosed and died just three months later, in excruciating pain. Those 90 days or so between his diagnosis and his death left a lifelong impression on me. 

Three years later, in 1989, I began my fellowship in medical oncology. I still remember one of my first patients with metastatic pancreatic cancer. There was so little we could offer her. All I could really do was try to control her pain. I found that profoundly frustrating; I had entered medicine to help people, yet here was a disease against which we seemed almost powerless.

I had studied immunology in college and had always been fascinated by the immune system. I believed that vaccines were among the most important medical advances of the 20th century. They had transformed our ability to prevent and, in some cases, control devastating diseases. I began to wonder whether we could harness the same power of the immune system to fight cancer.

I made a decision that would define my career: I would dedicate my life to finding a way to activate a patient’s own immune system to fight pancreatic cancer.


I set out to develop a cancer vaccine, and in 1997, I began testing a first-generation vaccine in patients whose localized pancreatic cancers had been surgically removed. The challenge was enormous: even after apparently successful surgery, within two years, 80% of patients would have a recurrence. We hoped that by stimulating the immune system, we could train it to recognize and eliminate the cancer cells that might remain in the body after surgery. This was a very different way of thinking about pancreatic cancer at the time.

Between 1997 and 2000, I treated the first six patients with this vaccine. Five developed measurable immune responses, and some patients remained free of disease even ten years later.

One patient will always stand out in my memory. He was diagnosed at age 71 and developed recurrent inflammation at the old vaccine injection sites, a sign of a persistent immune response. That inflammation continued for the rest of his life. Remarkably, he lived another 20 years and ultimately died of heart disease, not pancreatic cancer.

I never forgot these patients. Although six patients were far too few to establish that the vaccine prevented recurrence, their experiences strengthened my conviction that we were on the right path.


Pancreatic cancer has been particularly difficult to treat with immunotherapy because it has several ways of protecting itself from the immune system. Unlike some other cancers, it generally has fewer genetic mutations that help the immune system recognize it. It also creates a protective environment around the tumor, made up of dense fibrous tissue and immune-suppressing cells, that can prevent cancer-fighting immune cells from getting in and attacking the cancer. 

The exciting news is that we are beginning to understand these protective mechanisms and how to overcome them. New drugs that target cancer-driving mutations such as KRAS, one of the most common drivers of pancreatic cancer, approaches that change the environment surrounding the tumor, and cancer vaccines that target KRAS or proteins unique to a patient’s tumor may help make pancreatic cancers more vulnerable to immune attack.

We believe the greatest progress will come from combining these approaches with chemotherapy and immunotherapy to overcome resistance and produce more lasting responses.


Recent positive results from the Phase 3 INTerpath-001 study represent an important milestone for cancer immunotherapy. Adding an experimental personalized mRNA cancer vaccine to the immune checkpoint inhibitor KeytrudaⓇ (pembrolizumab) reduced the risk of melanoma recurrence or death after surgery compared with Keytruda alone. Although this study was conducted in melanoma, not pancreatic cancer, it provides the first compelling phase 3 evidence that therapeutic cancer vaccines can improve clinical outcomes in patients with cancer, and it is an exciting development for those of us who have spent decades working to bring this approach to patients.

For the past two decades, I have been evaluating pancreatic cancer vaccines in combination with different treatments that alter immune activity, with the goal of identifying the most effective strategies to prevent recurrence. We have identified a promising combination that has produced encouraging results, including signs of treatment response in tumor tissue, and are continuing to advance this approach through clinical development.


We have also taken an important step toward cancer prevention with a second-generation vaccine targeting mutated KRAS. In a recent study involving individuals at increased risk for pancreatic cancer, we demonstrated that the vaccine can induce immune responses against mutated KRAS that remain detectable for as long as two years. In some participants, small pancreatic cysts also resolved on MRI.

While these findings require further investigation, they raise the exciting possibility that vaccines might one day help prevent pancreatic cancer before it develops.

One of the greatest challenges in developing vaccines to prevent pancreatic cancer is that we still do not fully understand the biology of the disease in its earliest stages. We need to better understand the precancerous microenvironment – how immune cells, inflammatory signals, and surrounding tissue interact to either suppress or promote the development of cancer. This knowledge will be essential to designing vaccines that can generate durable immune responses capable of eliminating emerging cancer cells before they develop into invasive disease.

An equally important challenge is identifying the individuals who are most likely to benefit from a preventive vaccine. Pancreatic cancer is relatively uncommon in the general population, so vaccinating everyone is neither practical nor appropriate. We need better technologies to identify individuals at increased risk, including more sensitive blood-based biomarkers, improved imaging approaches, and molecular tests that can identify those whose pancreatic cysts are most likely to progress to cancer.

Ultimately, the combination of better risk prediction, early detection, and effective vaccines could make it possible to intervene before pancreatic cancer develops, rather than trying to treat it after it has become established.


During Pancreatic Cancer Awareness Month, what gives me the greatest hope is that we are no longer simply trying to find another drug to treat pancreatic cancer. We are beginning to approach the disease from multiple directions: understanding its earliest development, identifying individuals at increased risk, detecting it earlier, and developing treatments that can prevent recurrence or potentially prevent cancer from developing in the first place.

Some of these approaches are already showing encouraging results in clinical studies, although much work remains before they become standard care. I have spent decades working in this field, and I am more optimistic today than at any point in my career.

I want patients and families to know that progress is real, the scientific momentum is building, and we are increasingly moving toward a future in which pancreatic cancer is no longer the devastating diagnosis it is today.


Elizabeth Jaffee, MD, is an Associate Director of CRI’s Scientific Advisory Council; Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Dana and Albert “Cubby” Broccoli Professor of Oncology; Co-Director of the Skip Viragh Center for Pancreas Cancer; and an Associate Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy.


Join CRI in Shaping the Future of Immunotherapy

Support the pioneering work of CRI in advancing immunotherapy.

Father and son